FDA Issues Draft Guidance for Drug Delivery Devices
The regulatory body outlined new performance criteria for devices delivering drugs and biological products.
Updated on Oct. 29, 2026 in Biotech
Live Poll
Do you support stricter FDA oversight of drug delivery devices for patients?
In October 2026, the FDA released draft guidance focusing on the performance characteristics of drug delivery devices. The document establishes standardized recommendations for data submission throughout the regulatory application process.
Why it matters
This guidance ensures that companies provide essential information regarding how medical devices function when delivering human drugs and biological products. It aims to streamline the evaluation of device performance in investigational, marketing, and post-market change applications.
The FDA draft guidance defines technical parameters for assessing drug delivery performance across various hardware configurations. It establishes criteria for the data submitted in regulatory applications for devices delivering human drugs and biological products.
The players
Food and Drug Administration
The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices.
The details
The guidance specifically addresses the performance metrics required for combination products that integrate drugs with delivery hardware. By setting these expectations, the FDA intends to standardize how manufacturers document device performance during the product lifecycle.
Timeline
The FDA published the draft guidance in October 2026.
The Tech Race
This guidance extends the oversight framework established by the FDA's 21 CFR Part 4 regulations for combination products. It reflects an industry-wide push to standardize the testing of complex medical hardware in a rapidly evolving biotech sector.
While the guidance primarily affects manufacturers, it ultimately aims to improve the consistency and reliability of medical devices used by patients. Users may eventually see more standardized safety data and improved performance benchmarks for their drug delivery hardware.
The takeaway
Manufacturers should review these criteria to ensure their future regulatory submissions align with updated FDA expectations. Developing robust performance data now can prevent delays during the marketing or post-market change application phases.
Further reading
For more on the current standards for medical technology, see the Biotech section.
More information
Access the full technical requirements on the official FDA guidance document page.
Live Poll
Do you support stricter FDA oversight of drug delivery devices for patients?
